clinical trial · NCT04216927
NO During CPB in Neonates to Reduce Risk of AKI
Children's Hospital Medical Center, Cincinnati·phase3·recruiting·n = 40
AKICHD - Congenital Heart DiseaseSurgeryNitric OxideOxygen
brief summary
Acute kidney injury (AKI) following cardiac surgery for congenital heart defects (CHD) in children affects up to 60% of high risk-patients and is a major cause of both short- and long-term morbidity and mortality. Despite effort, to date, no successful therapeutic agent has gained widespread success in preventing this postoperative decline in renal function. Nitric oxide is an intricate regulator of acute inflammation and coagulation and is a potent vasodilator. The investigators hypothesize that nitric oxide, administered during cardiopulmonary bypass (CPB), may reduce the incidence of AKI.
started
Jan 10, 2023
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Jul 24, 2025
official title
Efficacy of Nitric Oxide Administration During Cardiopulmonary Bypass in Neonates at Reducing the Risk of Acute Kidney Injury
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol